reference/19466397

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19466397

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	580
issn	0006-291X
issueIdentifier	3
pageRange	575-580
publicationName	Biochemical and Biophysical Research Communications
startingPage	575
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_198be1621a05a7b6382d2ec966c36982 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c024788bcfdc3b4c24e4a1e47b96732d http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5d3914447cfc241a0aedc83f265c67ee
bibliographicCitation	Cho HJ, Baek KE, Nam IK, Park SM, Kim IK, Park SH, Im MJ, Ryu KJ, Yoo JM, Hong SC, Kim JW, Lee CW, Yoo J. PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer. Biochem Biophys Res Commun. 2011 Oct 28;414(3):575–80. doi: 10.1016/j.bbrc.2011.09.121. PMID: 21986528.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6f24112a9e7917c4efbb221be23ecb16 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7946ff1a3773af6cfa47a7d735f3dd99 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c28abbe4ed6535aef39b34899e71cf4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ba1862e5f5b5c9b19902ed9e168641b1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e23f6bcf4c4989ea2193f4e5d850ae3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8427-8311 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fb02d16406f60f21232ad43a109fbab2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_17f3a632665d3e457501b42190ef563b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f4668619e87443b0c942f0f96a72b338 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_62f8d67ea1f3ca3027a2d0db8ee708e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_da86bc0ef40a32b995098fbaa1d6b30e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2e866930da97da021f9e91dcb179baeb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e642f6428a4acaffa5048adbb7a1603 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c27933ac24bc4358d6785ea7bb32832
date	2011-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1016/j.bbrc.2011.09.121 https://pubmed.ncbi.nlm.nih.gov/21986528
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1008 https://portal.issn.org/resource/ISSN/0006-291X
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer
discusses	http://id.nlm.nih.gov/mesh/M0004505 http://id.nlm.nih.gov/mesh/M0374857 http://id.nlm.nih.gov/mesh/M0225971 http://id.nlm.nih.gov/mesh/M0328200 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0570420 http://id.nlm.nih.gov/mesh/M0220420 http://id.nlm.nih.gov/mesh/M0570417
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D002945Q000627 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D025521Q000378 http://id.nlm.nih.gov/mesh/D013274Q000188 http://id.nlm.nih.gov/mesh/D019008Q000235 http://id.nlm.nih.gov/mesh/D020730Q000378 http://id.nlm.nih.gov/mesh/D051966Q000502
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D045744 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D013274Q000473 http://id.nlm.nih.gov/mesh/D010766 http://id.nlm.nih.gov/mesh/D020730Q000235 http://id.nlm.nih.gov/mesh/D025521Q000235 http://id.nlm.nih.gov/mesh/D009361 http://id.nlm.nih.gov/mesh/D051966Q000235 http://id.nlm.nih.gov/mesh/D062947 http://id.nlm.nih.gov/mesh/D004789 http://id.nlm.nih.gov/mesh/D062949
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fbad7f823cba8baba2a01c97036aa930 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9305 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID5335 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID397

Total number of triples: 66.